期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 88, 期 -, 页码 108-122出版社
ELSEVIER
DOI: 10.1016/j.addr.2015.05.014
关键词
MicroRNA; Non-viral vector; Regenerative medicine; Scaffold; Stem cells; Tissue engineering; Viral vector
资金
- NIH [UH3 TR000505-03]
- AOSpine Foundation
- Guangdong Innovative and Entrepreneurial Research Team Program [2013S086]
- National Natural Science Foundation of China [51403243]
- China Postdoctoral Science Foundation [2014M552262]
MicroRNA (miRNA) directs post-transcriptional regulation of a network of genes by targeting mRNA. Although relatively recent in development, many miRNAs direct differentiation of various stem cells including induced pluripotent stem cells (iPSCs), a major player in regenerative medicine. An effective and safe delivery of miRNA holds the key to translating miRNA technologies. Both viral and nonviral delivery systems have seen success in miRNA delivery, and each approach possesses advantages and disadvantages. A number of studies have demonstrated success in augmenting osteogenesis, improving cardiogenesis, and reducing fibrosis among many other tissue engineering applications. A scaffold-based approach with the possibility of local and sustained delivery of miRNA is particularly attractive since the physical cues provided by the scaffold may synergize with the biochemical cues induced by miRNA therapy. Herein, we first briefly cover the application of miRNA to direct stem cell fate via replacement and inhibition therapies, followed by the discussion of the promising viral and nonviral delivery systems. Next we present the unique advantages of a scaffold-based delivery in achieving lineage-specific differentiation and tissue development. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据